Therapeutic Targeting of mTORC2 in mTORopathies

Brianne Dentel; Christine Ochoa Escamilla; Peter T Tsai

doi:10.1016/j.neuron.2019.11.026

Therapeutic Targeting of mTORC2 in mTORopathies

Neuron. 2019 Dec 18;104(6):1032-1033. doi: 10.1016/j.neuron.2019.11.026.

Authors

Brianne Dentel¹, Christine Ochoa Escamilla¹, Peter T Tsai²

Affiliations

¹ Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
² Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: peter.tsai@utsouthwestern.edu.

PMID: 31951535
DOI: 10.1016/j.neuron.2019.11.026

Abstract

Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant model, highlighting mTORC2 as a potential therapeutic target in mTORopathies.

Publication types

Comment

MeSH terms

Mechanistic Target of Rapamycin Complex 1
Mechanistic Target of Rapamycin Complex 2
Sirolimus*

Substances

Mechanistic Target of Rapamycin Complex 1
Mechanistic Target of Rapamycin Complex 2
Sirolimus